Long-term safety of adalimumab in clinical trials for adult patients with moderate to severe plaque psoriasis

被引：0

作者：

Leonardi, Craig ^{[1
]}

Papp, Kim ^{[2
,3
]}

Strober, Bruce ^{[4
,5
,6
]}

Thaci, Diamant ^{[7
]}

Warren, Richard B. ^{[8
]}

Tyring, Stephen ^{[9
]}

Arikan, Dilek ^{[10
]}

Karunaratne, Mahinda ^{[10
]}

Valdecantos, Wendell ^{[10
]}

机构：

[1] St Louis Univ Dept Dermatol, St Louis, MO USA

[2] Prob Med Res, Waterloo, ON, Canada

[3] K Papp Clin Res, Waterloo, ON, Canada

[4] Univ Connecticut, Dept Dermatol, Farmington, CT USA

[5] Prob Med Res, Farmington, CT USA

[6] K Papp Clin Res, Farmington, CT USA

[7] Univ Lubeck, Comprehens Ctr Inflammat Med, Lubeck, Germany

[8] Univ Manchester, Manchester Acad Hlth Sci Ctr, Dermatol Ctr, Manchester, Lancs, England

[9] Univ Texas Hlth Sci Ctr Houston, Dept Dermatol, Houston, TX 77030 USA

[10] AbbVie Inc, N Chicago, IL USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2016年 / 74卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

3822

引用

页码：AB259 / AB259

页数：1

共 50 条

[1] Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis
Leonardi, C.
Papp, K.
Strober, B.
Thaci, D.
Warren, R. B.
Tyring, S.
Arikan, D.
Karunaratne, M.
Valdecantos, W. C.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (01) : 76 - 85
[2] The long-term safety of adalimumab: An analysis of all adalimumab exposure in all moderate to severe psoriasis clinical trials
Reich, K.
Beason, J.
Lebwohl, M.
Rozzo, S.
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB154 - AB154
[3] Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis
Langley, R
Leonardi, C
Toth, D
Chen, D
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P2 - P2
[4] Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis
Gordon, K. B.
Lebwohl, M.
Papp, K. A.
Bachelez, H.
Wu, J. J.
Langley, R. G.
Blauvelt, A.
Kaplan, B.
Shah, M.
Zhao, Y.
Sinvhal, R.
Reich, K.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (03) : 466 - 475
[5] The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis A Comprehensive Analysis of All Adalimumab Exposure in All Clinical Trials
Leonardi, Craig
Papp, Kim
Strober, Bruce
Reich, Kristian
Asahina, Akihiko
Gu, Yihua
Beason, Joseph
Rozzo, Stephen
Tyring, Stephen
[J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2011, 12 (05) : 321 - 337
[6] Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis
Gniadecki, R.
Leonardi, C. L.
Gordon, K. B.
Gu, Y.
Geng, Z.
Nader, A.
Teixeira, H. D.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (08) : 1297 - 1304
[7] Short- and long-term efficacy and safety of adalimumab in a pivotal phase III study in adult patients with moderate to severe chronic plaque psoriasis
Menter, Alan
Papp, Kim
Leonardi, Craig
Frevert, Lisa
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB5 - AB5
[8] Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature
Moore, Angela Y.
Richardson, Blakely S.
[J]. CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2010, 3 : 49 - 58
[9] Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials
Langley, R. G.
Kimball, A. B.
Nakagawa, H.
Xu, W.
Pangallo, B.
Osuntokun, O. O.
Agada, N.
Reich, K.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (02) : 333 - 339
[10] Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis
Umezawa, Y.
Nakagawa, H.
Niiro, H.
Ootaki, K.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (11) : 1957 - 1960

← 1 2 3 4 5 →